FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 158 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... March 6, 2025 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 EMA Recommends Granting a Marketing Authorisation for Degarelix Accord September 14, 2023 Immunotherapy approved for some people with advanced melanoma in England December 21, 2021 Load more HOT NEWS “Your Stories” Podcast: Amplifying Patient Voices NICE doesn’t recommend olaparib for patients with certain prostate cancers Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors Merging the Histologic and Molecular Data Into an Integrated Score Significantly...
